| Drug Name |
Risedronic acid |
| Drug ID |
BADD_D01950 |
| Description |
Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959]. |
| Indications and Usage |
Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis[FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
M05BA07 |
| DrugBank ID |
DB00884
|
| KEGG ID |
D08484
|
| MeSH ID |
D000068296
|
| PubChem ID |
5245
|
| TTD Drug ID |
D0PA5S
|
| NDC Product Code |
Not Available |
| UNII |
KM2Z91756Z
|
| Synonyms |
Risedronic Acid | 1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate | Atelvia | Risedronate Sodium | 2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate | 2-(3-pyridinyl)-1-hydroxyethylidenebisphosphonate | Risedronic Acid, Monosodium Salt | Actonel | Risedronate | Bisphosphonate Risedronate Sodium | Risedronate Sodium, Bisphosphonate | Sodium, Bisphosphonate Risedronate |
